GATA3 targets semaphorin 3B in mammary epithelial cells to suppress breast cancer progression and metastasis

P. Shahi, C. Y. Wang, J. Chou, C. Hagerling, H. Gonzalez Velozo, A. Ruderisch, Y. Yu, M. D. Lai, Z. Werb

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Semaphorin 3B (SEMA3B) is a secreted axonal guidance molecule that is expressed during development and throughout adulthood. Recently, SEMA3B has emerged as a tumor suppressor in non-neuronal cells. Here, we show that SEMA3B is a direct target of GATA3 transcriptional activity. GATA3 is a key transcription factor that regulates genes involved in mammary luminal cell differentiation and tumor suppression. We show that GATA3 relies on SEMA3B for suppression of tumor growth. Loss of SEMA3B renders GATA3 inactive and promotes aggressive breast cancer development. Overexpression of SEMA3B in cells lacking GATA3 induces a GATA3-like phenotype and higher levels of SEMA3B are associated with better cancer patient prognosis. Moreover, SEMA3B interferes with activation of LIM kinases (LIMK1 and LIMK2) to abrogate breast cancer progression. Our data provide new insights into the role of SEMA3B in mammary gland and provides a new branch of GATA3 signaling that is pivotal for inhibition of breast cancer progression and metastasis.

Original languageEnglish
Pages (from-to)5567-5575
Number of pages9
JournalOncogene
Volume36
Issue number40
DOIs
Publication statusPublished - Oct 5 2017
Externally publishedYes

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Cancer Research

Fingerprint Dive into the research topics of 'GATA3 targets semaphorin 3B in mammary epithelial cells to suppress breast cancer progression and metastasis'. Together they form a unique fingerprint.

  • Cite this

    Shahi, P., Wang, C. Y., Chou, J., Hagerling, C., Gonzalez Velozo, H., Ruderisch, A., Yu, Y., Lai, M. D., & Werb, Z. (2017). GATA3 targets semaphorin 3B in mammary epithelial cells to suppress breast cancer progression and metastasis. Oncogene, 36(40), 5567-5575. https://doi.org/10.1038/onc.2017.165